Status:

COMPLETED

Diabetes Risk Communication Tool Evaluation

Lead Sponsor:

National University of Singapore

Collaborating Sponsors:

National Medical Research Council (NMRC), Singapore

Conditions:

Type 2 Diabetes

Eligibility:

All Genders

30-60 years

Phase:

NA

Brief Summary

Prevention for Type 2 Diabetes (T2D)has been vast but with limited success. While Singaporeans have high knowledge about T2D, its symptoms, and risk factors, healthy practices are still sub-optimal. U...

Eligibility Criteria

Inclusion

  • Aged 30-60 years;
  • Singapore citizen, or permanent resident
  • Able to read and understand English,
  • Have had a health screening with blood pressure, triglycerides, and HbA1C done within the last 3 months
  • At least one risk factor for Type 2 Diabetes (BMI ≥ 23 kg/m2, blood pressure ≥130/85 mmHg or receiving therapy for hypertension, triglycerides ≥1.7mmol/L or HbA1c ≥5.7%)

Exclusion

  • \- Diagnosis of any event of cardiovascular disease, kidney issues, or type 2 diabetes

Key Trial Info

Start Date :

June 20 2022

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 7 2023

Estimated Enrollment :

460 Patients enrolled

Trial Details

Trial ID

NCT05427890

Start Date

June 20 2022

End Date

August 7 2023

Last Update

September 21 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

National University of Singapore

Singapore, Singapore

Diabetes Risk Communication Tool Evaluation | DecenTrialz